These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 17941861)

  • 1. Efficacy of continuous subcutaneous insulin infusion in Type 1 diabetes: a 2-year perspective using the established criteria for funding from a National Health Service.
    Giménez M; Conget I; Jansà M; Vidal M; Chiganer G; Levy I
    Diabet Med; 2007 Dec; 24(12):1419-23. PubMed ID: 17941861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study.
    Brorsson AL; Viklund G; Örtqvist E; Lindholm Olinder A
    Pediatr Diabetes; 2015 Nov; 16(7):546-53. PubMed ID: 25327782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes DA; Gamble C;
    BMJ; 2019 Apr; 365():l1226. PubMed ID: 30944112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) in paediatric Type 1 diabetes: a multicentre matched-pair cohort analysis over 3 years.
    Jakisch BI; Wagner VM; Heidtmann B; Lepler R; Holterhus PM; Kapellen TM; Vogel C; Rosenbauer J; Holl RW;
    Diabet Med; 2008 Jan; 25(1):80-5. PubMed ID: 18199134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial.
    Hoogma RP; Hammond PJ; Gomis R; Kerr D; Bruttomesso D; Bouter KP; Wiefels KJ; de la Calle H; Schweitzer DH; Pfohl M; Torlone E; Krinelke LG; Bolli GB;
    Diabet Med; 2006 Feb; 23(2):141-7. PubMed ID: 16433711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of multiple daily insulin therapy with continuous subcutaneous insulin infusion therapy in adolescents with type 1 diabetes mellitus: a single-center experience from Turkey.
    Abaci A; Atas A; Unuvar T; Demir K; Bober E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 2009 Jun; 22(6):539-45. PubMed ID: 19694201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study.
    Rosenlund S; Hansen TW; Andersen S; Rossing P
    Diabet Med; 2015 Nov; 32(11):1445-52. PubMed ID: 26331364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.
    Herman WH; Ilag LL; Johnson SL; Martin CL; Sinding J; Al Harthi A; Plunkett CD; LaPorte FB; Burke R; Brown MB; Halter JB; Raskin P
    Diabetes Care; 2005 Jul; 28(7):1568-73. PubMed ID: 15983302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of continuous subcutaneous insulin infusion versus multiple daily injections in emerging adults with type 1 diabetes is associated with better clinical engagement but not glycaemic control.
    Chai TYL; Farrell K; Holmes-Walker DJ
    Intern Med J; 2023 Feb; 53(2):255-261. PubMed ID: 34561942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.
    Jeitler K; Horvath K; Berghold A; Gratzer TW; Neeser K; Pieber TR; Siebenhofer A
    Diabetologia; 2008 Jun; 51(6):941-51. PubMed ID: 18351320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous subcutaneous insulin infusion therapy: effects on quality of life.
    Scheidegger U; Allemann S; Scheidegger K; Diem P
    Swiss Med Wkly; 2007 Aug; 137(33-34):476-82. PubMed ID: 17990132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial.
    Weintrob N; Benzaquen H; Galatzer A; Shalitin S; Lazar L; Fayman G; Lilos P; Dickerman Z; Phillip M
    Pediatrics; 2003 Sep; 112(3 Pt 1):559-64. PubMed ID: 12949284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term benefits of continuous subcutaneous insulin infusion in children with Type 1 diabetes: a 4-year follow-up.
    Sulli N; Shashaj B
    Diabet Med; 2006 Aug; 23(8):900-6. PubMed ID: 16911629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D; Crazzolara D; Maran A; Costa S; Dal Pos M; Girelli A; Lepore G; Aragona M; Iori E; Valentini U; Del Prato S; Tiengo A; Buhr A; Trevisan R; Baritussio A
    Diabet Med; 2008 Mar; 25(3):326-32. PubMed ID: 18307459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: efficacy, acceptability and quality of life.
    Bruttomesso D; Pianta A; Crazzolara D; Scaldaferri E; Lora L; Guarneri G; Mongillo A; Gennaro R; Miola M; Moretti M; Confortin L; Beltramello GP; Pais M; Baritussio A; Casiglia E; Tiengo A
    Diabet Med; 2002 Aug; 19(8):628-34. PubMed ID: 12147142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years.
    Linkeschova R; Raoul M; Bott U; Berger M; Spraul M
    Diabet Med; 2002 Sep; 19(9):746-51. PubMed ID: 12207811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy.
    Shalitin S; Gil M; Nimri R; de Vries L; Gavan MY; Phillip M
    Diabet Med; 2010 Mar; 27(3):339-47. PubMed ID: 20536498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability.
    Pickup JC; Kidd J; Burmiston S; Yemane N
    Diabetes Metab Res Rev; 2006; 22(3):232-7. PubMed ID: 16389648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.